Drugs / UF-KURE-BCMA CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06698744 | Sep 2025 → Dec 2026 | plasma cell myeloma | David Wald | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UF-KURE-BCMA CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06698744 ↗ |
| Action | Deplete | “targets the BCMA receptor to eliminate multiple myeloma cells” NCT06698744 ↗ |
| Modality | Cell therapy | “UF-KURE-BCMA is an autologous CAR-T cell therapy” NCT06698744 ↗ |